Today: 9 November 2025
Subscribe
Browse Category

Healthcare Stocks News 29 September 2025 - 30 October 2025

Cardinal Health (NYSE: CAH) Stock Soars to Record High on Blowout Earnings and Raised Outlook

Cardinal Health (NYSE: CAH) Stock Soars to Record High on Blowout Earnings and Raised Outlook

Stock Hits All-Time High After Earnings Surprise Cardinal Health’s stock price surged to an all-time high on October 30, 2025, after the company delivered much better-than-expected quarterly results. Shares soared ~13% in one day, briefly trading above $190 intraday and settling around $185 – levels never seen before investing.com 247wallst.com. This spike extended Cardinal’s impressive rally (the stock is up over 50% year-on-year), as investors reacted enthusiastically to the latest earnings and outlook. The one-day jump came amid heavy trading volume and put Cardinal Health among the top gainers on the NYSE that day 247wallst.com. The broad market was mixed,
30 October 2025
 ·  ·  ·  ·  · 
Molina Healthcare (MOH) Stock Plunges 18% on Earnings Shock – What’s Next?

Molina Healthcare (MOH) Stock Plunges 18% on Earnings Shock – What’s Next?

Q3 Earnings Shock Triggers Selloff Molina Healthcare’s third-quarter earnings report sparked a major selloff in its stock this week. The Medicaid and Obamacare-focused insurer delivered adjusted Q3 earnings of just $1.84 per share, far below analyst expectations of around $3.90 reuters.com. On a GAAP basis, net income collapsed to $79 million ($1.51/share) from $326 million ($5.65/share) a year earlier nasdaq.com – a 73% drop, underscoring the steep profit hit. Revenues actually climbed 11% year-over-year to $11.48 billion nasdaq.com, exceeding forecasts, as Molina added members and benefited from recent acquisitions. But investors zeroed in on the earnings miss and margin plunge, dumping
23 October 2025
 ·  ·  ·  ·  · 
Intuitive Surgical (ISRG) Stock Explodes 17% on Q3 Blowout – Is $600 Next?

Intuitive Surgical (ISRG) Stock Explodes 17% on Q3 Blowout – Is $600 Next?

Q3 Earnings Blowout and Stock Reaction Intuitive Surgical crushed expectations for the quarter ended Sept 30, 2025. 3Q revenue was $2.51 billion, up 23% from a year ago, versus analyst forecasts of ~$2.40 billion reuters.com. Adjusted EPS came in at $2.40 (GAAP $1.95), easily above the ~$1.99 consensus reuters.com globenewswire.com. The company reported $867 million in non-GAAP net income (versus $669 M a year prior) globenewswire.com. Notably, Intuitive repurchased $1.92 billion of stock in Q3, burning 4 million shares, which also supported EPS globenewswire.com. “We’re pleased with our strong results this quarter, underscored by continued growth in customer use and adoption of our Ion and
22 October 2025
 ·  ·  ·  ·  · 
Intuitive Surgical Stock Primed for Rally on FDA Approvals and Congressional Buying

Intuitive Surgical Stock Primed for Rally on FDA Approvals and Congressional Buying

Stock Performance & Analyst Consensus Intuitive’s stock has been volatile in 2025. It gained ground last week on optimism (e.g. up ~2.7% on Oct. 17) and now sits around $446 investing.com marketbeat.com. Over the past year, the price swung between about $425 and $616 investing.com. At ~$446, ISRG trades at a high single-digit P/E (~60x) compared to the medtech sector, but analysts argue much of Intuitive’s growth is already priced in. Institutional sentiment is upbeat: 22 of 32 surveyed analysts rate ISRG a Buy, with an average 12-month target of roughly $576 investing.com (implying ~29% upside). For example, RBC Capital
19 October 2025
 ·  ·  ·  ·  · 
Abbott (ABT) Stock Slides on Mixed Q3 Results – Is a Rally Over?

Abbott (ABT) Stock Slides on Mixed Q3 Results – Is a Rally Over?

Price and Performance Abbott’s stock has been trading in a tight range around $128–$133 in mid-October 2025. On Oct 15, the price was about $128 – down 3.5% intraday reuters.com. Over the past few trading days ABT fell from $131.38 (Oct 13 close) and $133.27 (Oct 14) to $128.77 stockanalysis.com. In context, ABT’s YTD gain is roughly 18%, outpacing the broad market. (By comparison, the S&P 500 is up ~13% YTD nasdaq.com.) The stock’s forward P/E is about 24–25 (slightly lower than a few months ago) tradingview.com, suggesting analysts see modest growth ahead. Q3 Results and Guidance Abbott’s Q3 earnings
15 October 2025
 ·  ·  ·  ·  · 
Oscar Health (OSCR) Stock Surges on Expansion Plans – What Analysts Are Saying

Oscar Health (OSCR) Stock Skyrockets – Major News & Analyst Insights (Oct 2025)

Key Facts: Oscar Health’s stock recently jumped to roughly $21.5 on Oct 3, 2025 (up ≈11% that day) indmoney.com. Over the past week, the stock is up about 8% marketscreener.com. In Q2 2025, Oscar reported $2.9 billion revenue (+28–30% YoY) but a $228 million net loss ($0.89/share) due to a high medical loss ratio tradingview.com. Management has reaffirmed full-year 2025 guidance (revenues ~$11.2–11.3 B, operating income $225–275 M) at the Wells Fargo conference ainvest.com ainvest.com, and in July raised its revenue outlook to ~$12.0–12.2 B (but warned medical costs would be higher, with MLR ~86–87%) investing.com. Analysts are broadly bearish: MarketBeat shows a consensus “Strong
3 October 2025
 ·  ·  ·  ·  · 
Oscar Health (OSCR) Stock Surges on Expansion Plans – What Analysts Are Saying

Oscar Health (OSCR) Stock Surges on Expansion Plans – What Analysts Are Saying

Stock Performance (Oct 3, 2025) As of this afternoon’s trading on Oct 3, Oscar Health shares are up ~2.8% around $19.81. The stock opened near $19.82 and is trading in a tight range (today’s low ~$19.80, high ~$19.95). Yesterday (Oct 2) it closed at $19.28 (+2.0%), continuing a rebound from late-September lows (it had hit ~$17 in mid-September). Volume so far is modest (~0.2M vs a 3‑month average of ~0.5M). Year-to-date Oscar’s stock is up roughly 30–40% from 2024 lows (last fall it traded under $15), and it has outpaced many traditional insurers on a percentage basis this year nasdaq.com.
3 October 2025
 ·  ·  ·  ·  ·  · 
Hims & Hers Health Stock Skyrockets amid Weight-Loss Mania – But FDA Scrutiny Looms

Hims & Hers Health Stock Skyrockets amid Weight-Loss Mania – But FDA Scrutiny Looms

“It’s never been more clear that we are delivering exactly what millions of people have been waiting for,” said HIMS CEO Andrew Dudum after Q2 results investors.hims.com. With analysts ranging from “Sell” to “Buy”, and social media buzzing, Hims & Hers remains one of 2025’s most talked-about healthcare stocks – its fortunes tightly tied to both the telehealth boom and regulatory oversight. Sources: Recent filings and press releases investors.hims.com investors.hims.com; Reuters and AP news on regulatory actions reuters.com reuters.com reuters.com; analyst reports and SEC filings quiverquant.com marketbeat.com; and HIMS-sponsored studies/news investors.hims.com fox10tv.com. (All figures as reported; analysis current as of
29 September 2025
 ·  ·  ·  ·  ·  · 
Go toTop